Dose-dependent effect of angiotensin II on human erythropoietin production

被引：0

作者：

Freudenthaler S.M. ^{[1
]}

Lucht I. ^{[1
]}

Schenk T. ^{[1
]}

Brink M.

Gleiter C.H. ^{[1
,2
]}

机构：

[1] Klinische Pharmakologie, Universität Göttingen, Gottingen

[2] Department of Clinical Pharmacology, University of Tübingen, D-72074 Tübingen

来源：

Pflügers Archiv | 2000年 / 439卷 / 6期

关键词：

Angiotensin II; Erythropoietin; Healthy volunteers; Insulin-like growth factor I (IGF-I);

D O I：

10.1007/s004249900238

中图分类号：

学科分类号：

摘要：

Current evidence suggests that angiotensin II may be involved in the regulation of renal erythropoietin (EPO) production. The present study assessed the role of angiotensin II (A II) in different doses in the control of EPO production in humans. In a parallel, randomized, placebo-controlled open design, 60 healthy male volunteers received a 6-h intravenous infusion of: placebo (placebo, electrolyte solution), a pressor dose of A II (1-3 μg/min; A II press), a combination of a pressor dose of A II and the selective AT1-receptor blocker losartan, 50 mg (A II press + L), a subpressor dose of A II (0.0375-0.15 μg/min; A II subpress) and a combination of a subpressor dose of A II and losartan (A II subpress + L). A II press treatment resulted in a significant increase of the maximum EPO concentration (C(maxEPO), 41% higher versus placebo) and the amount of EPO produced in 24 h (AUC(EPO(0-24 h)), 61% larger versus placebo), A II subpress treatment increased C(maxEPO) (35% higher versus placebo) and AUC(EPO(0-24 h)) (34% larger versus placebo). A II press + L and A-II subpress + L treatments did not significantly increase C(maxEPO) and AUC(EPO(0-24 h)) compared to placebo. A II affects EPO production in a dose-dependent manner. The signal seems to be mediated via AT1-receptors. A II appears to be one modulator EPO production in humans.

引用

页码：838 / 844

页数：6

共 30 条

[1]

Fisher J.W., Samuels A.I., Langston J.W., Effects of angiotensin and renal artery constriction on erythropoietin production, J Pharmacol Exp Ther, 157, pp. 618-625, (1967)

[2]

Freudenthaler S.M., Schenck T., Lucht I., Gleiter C.H., Fenoterol stimulates human erythropoietin production via activation of the renin angiotensin system, Br J Clin Pharmacol, 48, pp. 631-634, (1999)

[3]

Freudenthaler S.M., Schreeb K.H., Korner T., Gleiter C.H., Angiotensin II increases erythropoietin production in healthy human volunteers, Eur J Clin Invest, 29, pp. 816-823, (1999)

[4]

Gleiter C.H., Posttransplant erythrocytosis: A model for the investigation of the pharmacological control of renal erythropoietin production?, Int J Clin Pharmacol Ther, 34, pp. 489-492, (1996)

[5]

Gleiter C.H., Freudenthaler S., Delabar U., Eckardt K.U., Muhlbauer B., Gundert-Remy U., Osswald H., Erythropoietin production in healthy volunteers subjected to controlled hemorrhagia: Evidence against a role of adenosine, Br J Clin Pharmacol, 42, pp. 729-735, (1996)

[6]

Gleiter C.H., Becker T., Wenzel J., Erythropoietin production in healthy volunteers subjected to controlled hypobaric hypoxia: Further evidence against a role for adenosine, Br J Clin Pharmacol, 44, pp. 203-205, (1997)

[7]

Gleiter C.H., Becker T., Schreeb K.H., Freudenthaler S., Gundert-Remy U., Fenoterol but not dobutamine increases erythropoietin production in humans, Clin Pharmacol Ther, 61, pp. 669-676, (1997)

[8]

Gleiter C.H., Schreeb K.H., Goldbach S., Herzog S., Cunze T., Kuhn W., Fenoterol increases erythropoietin concentrations during tocolysis, Br J Clin Pharmacol, 45, pp. 157-159, (1998)

[9]

Gould A.B., Goodman S., DeWolf R., Onesti G., Swartz C., Interrelation of the renin system and erythropoietin in rats, J Lab Clin Med, 96, pp. 523-534, (1980)

[10]

Gunga H.C., Wittels P., Gunther T., Kanduth B., Vormann J., Rocker L., Kirsch K., Erythropoietin in 29 men during and after prolonged physical stress combined with food and fluid deprivation, Eur J Appl Physiol, 73, pp. 11-16, (1996)

← 1 2 3 →